60 DEGREES PHARMACEUTICALS, INC.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $1.5M-9.0% | $1.7M-22.6% | $2.1M | — |
| Accounts Receivable | $510K+4.7% | $487K+110.4% | $231K+403.3% | $46K |
| Prepaid and Other Assets | $978K-8.5% | $1.1M-75.7% | $4.4M+2090.7% | $201K |
| Short-Term Investments | $1.2M-28.2% | $1.7M | — | — |
| Inventory (Note 3) | $657K+48.4% | $443K-5.0% | $466K-10.1% | $519K |
| Total Current Assets | $4.9M-9.1% | $5.4M-25.6% | $7.2M+559.0% | $1.1M |
| Property and Equipment, net (Note 4) | $246K+64.5% | $150K+159.4% | $58K+171.2% | $21K |
| Long-Term Prepaid Expense | $0-100.0% | $66K-72.7% | $243K | — |
| Intangible Assets, net (Note 5) | $224K+42.8% | $157K-30.9% | $227K+38.4% | $164K |
| Total Other Assets | $224K+0.5% | $223K-53.8% | $483K+173.3% | $177K |
| Total Assets | $5.4M-6.8% | $5.8M-26.0% | $7.8M+500.0% | $1.3M |
| Accounts Payable and Accrued Expenses | $1.5M+44.8% | $1.0M+99.1% | $506K-33.3% | $759K |
| SBA EIDL (including accrued interest) (Note 7) | $144K-2.1% | $147K-2.1% | $150K | — |
| Derivative Liabilities (Note 8) | $375K-41.5% | $641K-72.2% | $2.3M+104.2% | $1.1M |
| Total Current Liabilities | $1.8M+11.2% | $1.7M-41.6% | $2.8M-88.1% | $23.9M |
| Total Long-Term Liabilities | $144K-2.1% | $147K-2.1% | $150K-90.1% | $1.5M |
| Total Liabilities | $2.0M+10.1% | $1.8M-39.6% | $3.0M-88.3% | $25.4M |
| Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively (Note 6) | $9.6M+0.0% | $9.6M-2.9% | $9.9M | — |
| Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,163,142 and 141,749 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively(1) (Note 6) | $116+728.6% | $14+40.0% | $10-95.8% | $239 |
| Additional Paid-in Capital | $41.6M+19.5% | $34.9M+27.0% | $27.5M+431.6% | $5.2M |
| Accumulated Other Comprehensive Income | $143K+5.3% | $135K-0.1% | $136K+83.9% | $74K |
| Accumulated Deficit | -$47.9M-18.2% | -$40.5M-24.4% | -$32.6M-13.1% | -$28.8M |
| 60P Shareholders’ Equity: | $3.5M-14.2% | $4.0M-17.1% | $4.9M+120.7% | -$23.6M |
| Noncontrolling Interest | -$84K-3.9% | -$81K-11.9% | -$72K+87.4% | -$572K |
| Total Shareholders’ Equity | $3.4M-14.6% | $4.0M-17.6% | $4.8M+119.9% | -$24.1M |
| Total Liabilities and Shareholders’ Equity | $5.4M-6.8% | $5.8M-26.0% | $7.8M+500.0% | $1.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.